EUVIMEDEUVIMED entdecken
Leserbrief

Tirzepatide for Congenital Generalized Lipodystrophy

Svetlana Ten, Amrit Bhangoo, Christoph Buettner

New England Journal of Medicine · 13.02.2025 · 392 (7) · 717-719

DOI: 10.1056/nejmc2413871 ↗

Kurz gefasst

Leserbrief in der Zeitschrift New England Journal of Medicine, erschienen am 13.02.2025. Verfasst von Svetlana Ten und 2 weiteren Autor:innen. Beteiligte Einrichtung: Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 1 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Two patients with congenital generalized lipodystrophy type 1 due to a variant in AGPAT2 (c.589-2A→G) who had been receiving insulin and metreleptin were switched to tirzepatide and were successfully weaned off other therapy.

Autor:innen und Institutionen

  • Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ.
  • Children's Hospital of Orange County, Orange, CA.

Zitieren

APA

Ten, S., Bhangoo, A., & Buettner, C. (2025). Tirzepatide for Congenital Generalized Lipodystrophy. New England Journal of Medicine, 392(7), 717-719. https://doi.org/10.1056/nejmc2413871

Vancouver

Ten S, Bhangoo A, Buettner C. Tirzepatide for Congenital Generalized Lipodystrophy. New England Journal of Medicine. 2025;392(7):717-719. doi:10.1056/nejmc2413871

BibTeX
@article{Ten2025,
  author = {Ten, Svetlana and Bhangoo, Amrit and Buettner, Christoph},
  title = {Tirzepatide for Congenital Generalized Lipodystrophy},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {392},
  number = {7},
  pages = {717--719},
  doi = {10.1056/nejmc2413871}
}
Kostenlos starten →